Fundamentals Hub
EDSA Edesa Biotech, Inc.
EDSA financial statements, revenue, balance sheet, cash flow, and SEC filings
Showing 3 of 13 annual and 0 of 50 quarterly periods.
Full history available with a free account or via API.
▼ Company Profile
Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$13.98M (Mar 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
A1
Fiscal Year End
September (0930)
Phone
(905) 475-1234
EIN
000000000
Headquarters
MARKHAM
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names:
Stellar Biotechnologies, Inc. (2012–2019)
▼ Key Metrics (TTM)
As of Jun 30, 2026Financials
Revenue
-
Net Income
$-14.10M
Total Assets
$12.72M
Total Equity
$8.81M
Total Debt
-
Free Cash Flow
-
Ratios
Return on Equity
-160%
Return on Assets
-110.9%
Current Ratio
2.76x
Sources and calculation details
Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.
Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.
Annual (FY)
Quarterly 🔒
Chart 🔒
| Metric | FY2025 📄 | FY2024 📄 | FY2023 📄 |
|---|---|---|---|
| Income Statement | |||
| REVENUE | |||
| OPERATING EXPENSES | |||
| R&D Expense | $3.67M | $2.88M | $4.79M |
| SG&A Expense | $4.24M | $4.13M | $4.43M |
| Operating Income | $-7.91M | $-7.01M | $-9.22M |
| NON-OPERATING INCOME / EXPENSE | |||
| Interest Income | $2.56K | $153.50K | $289.85K |
| Other Income/Expense | $726.84K | $845.50K | $849.14K |
| Pretax Income | $-7.18M | $-6.17M | $-8.37M |
| Income Tax | $800 | $800 | $800 |
| Net Income | $-7.19M | $-6.17M | $-8.37M |
| PER SHARE & SUPPLEMENTAL | |||
| EBITDA | $-7.79M | $-6.83M | $-9.04M |
| Depreciation & Amortization | $119.27K | $186.05K | $183.47K |
| Balance Sheet | |||
| ASSETS | |||
| Cash & Equivalents | $10.80M | $1.00M | $5.40M |
| Other Current Assets | $77.84K | $367.39K | $448.91K |
| Current Assets | $11.51M | $1.68M | $6.44M |
| PP&E (Net) | - | $0 | $8.70K |
| Intangible Assets | $1.98M | $2.08M | $2.18M |
| Noncurrent Assets | $2.02M | $2.14M | $2.45M |
| Total Assets | $13.53M | $3.81M | $8.89M |
| LIABILITIES | |||
| Accounts Payable | $1.08M | $1.81M | $1.75M |
| Current Liabilities | $1.08M | $1.83M | $1.82M |
| Noncurrent Liabilities | - | $0 | $19.77K |
| Total Liabilities | - | $1.83M | $1.84M |
| EQUITY | |||
| Common Stock | $54.52M | $47.24M | $46.64M |
| Additional Paid-in Capital | $14.75M | $13.58M | $13.04M |
| Retained Earnings | $-65.91M | $-58.59M | $-52.42M |
| Accumulated OCI | $-165.77K | $-242.61K | $-214.65K |
| Total Equity | $12.45M | $1.98M | $7.05M |
| Total Liabilities & Equity | $13.53M | $3.81M | $8.89M |
| SUPPLEMENTAL | |||
| Shares Outstanding | 7.14M | 3.25M | 3.08M |
| Check: A − (L + E + NCI) | $1.08M | - | - |
| Cash Flow Statement | |||
| Cash from Operations | $-7.32M | $-4.89M | $-6.64M |
| Capital Expenditures | - | - | $0 |
| Cash from Investing | - | - | $0 |
| Cash from Financing | $17.03M | $592.03K | $4.83M |
| Free Cash Flow | - | - | $-6.64M |
| Beginning Cash (CFS) | $1.04M | $5.36M | - |
| Net Change in Cash | - | - | - |
| Effect of FX on Cash | $46.22K | $-25.90K | $76.85K |
| Calculated Ending Cash | - | - | - |
| Cash per BS | $10.80M | $1.00M | $5.40M |
| Cash scope difference (CFS − BS) | $-7.83K | $37.32K | $-38.60K |
| Cash per CFS | $10.79M | $1.04M | $5.36M |
Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.
Create Free Account Log In🔒
Quarterly data and charts require a free account
Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.
▼ Frequently Asked Questions
Is Edesa Biotech, Inc. profitable?
No. Edesa Biotech, Inc. reported $-14.10M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.